Ionis scores transformational FDA label expansion for Tryngolza

Ionis Pharmaceuticals' antisense drug Tryngolza (olezarsen) has received a major FDA label expansion to treat adults with severe hypertriglyceridemia (sHTG), a population of roughly 3 million people in the U.S., including about 1 million considered high‑risk; the approval marks a transformational growth opportunity for the wholly owned asset and positions Tryngolza as the first FDA‑approved therapy shown to reduce both triglycerides and the risk of acute pancreatitis in sHTG patients.

The FDA cleared Tryngolza as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG (triglycerides ≥500 mg/dL), building on its prior approval in 2024 for the ultra‑rare familial chylomicronemia syndrome (FCS); in the pivotal CORE and CORE2 trials, Tryngolza cut fasting triglycerides by up to 72% versus placebo at six months and maintained those reductions at 12 months, while also lowering acute pancreatitis events by up to about 85–91% compared with placebo.

Ionis plans to launch Tryngolza for sHTG in the U.S. in July 2026, with a monthly subcutaneous injection that inhibits production of apoC‑III, a key regulator of triglyceride metabolism; analysts view the expanded indication as critical to reaching potential blockbuster sales expectations for the drug, and the company has also submitted a label‑expansion application to the European Medicines Agency (EMA) for sHTG.